In this context, Tsimafeyeu and his colleagues conducted a prospective, non-randomized trial to evaluate the toxicity and efficacy of a regimen of low-dose GM-CSF, IFN-α, and IL-2 administered postoperatively to patients with high-risk RCC. The gene discussed is IL2; the disease is renal cell carcinoma.